Kansas City Cancer Center Adopts TomoTherapy Platform to Advance Patient Care | TomoTherapy Incorporated
LinkedIn Login

Connect healthcare products, companies and hospitals with your LinkedIn network.

Facebook Login

Interact with your Facebook network around healthcare products, companies and hospitals.

Login With Facebook
MedicExchange Login

Enjoy Premium Access as a MedicExchange Member.

       Enter Your Email Address to Receive a
Copy of MedicExhange Member Demograhpics

Facebook Twitter Linkedin
Facebook: MedicExchange
Twitter: MedicExchange
Healthcare Company News TomoTherapy Incorporated Kansas City Cancer Center Adopts TomoTherapy Platform to Advance Patient Care

Kansas City Cancer Center Adopts TomoTherapy Platform to Advance Patient Care

Company News - TomoTherapy Incorporated

KCCC Becomes First US Oncology, Inc., Affiliate to Install Innovative Radiation Therapy Treatment Solution

TomoTherapy Incorporated (NASDAQ: TOMO) announced that Kansas City Cancer Center (KCCC) has commenced treating patients with the TomoTherapy Hi·Art treatment system, a versatile, CT scanner-based device, that integrates image guidance for increased treatment accuracy and helical radiation therapy delivery for enhanced tumor targeting. KCCC becomes the first TomoTherapy treatment center in Kansas City, and the first US Oncology, Inc., affiliate to adopt TomoTherapy technology in the fight against cancer.

The TomoTherapy Hi·Art system has been installed at KCCC’s new Shawnee Mission location, one of 11 KCCC facilities in the Kansas City area. KCCC is a member of the US Oncology network, which treats more than 650,000 patients a year, or approximately 15 percent of all cancer patients in the U.S.

TomoTherapy treatments began at KCCC-Shawnee Mission in late July. According to Radiation Oncologist James Coster, M.D., many Kansas City area cancer patients have already benefitted from the introduction of this groundbreaking technology. “It’s so precise that radiation can be localized to the cancer itself while nearly eliminating dose to the surrounding healthy tissues,” says Dr. Coster. “It completely changes the way we fight cancers of the head, neck, breast and prostate, and the impact we can make on overall patient health.”

Fred Robertson, M.D., CEO for TomoTherapy Inc., sees the KCCC installation as another key milestone for the company. “TomoTherapy is excited to be working with US Oncology and KCCC. We believe that with TomoTherapy’s advanced, image-guided radiotherapy platform, KCCC will be able to significantly improve patient care.”

About Kansas City Cancer Center and US Oncology, Inc.

Kansas City Cancer Center is a full service cancer healthcare practice, with 11 offices throughout the Kansas City region.  KCCC provides a wide range of patient support, including oncology treatment, diagnostic imaging, genetic risk evaluation and testing and survivorship wellness programs. For more information on KCCC, please visit www.kccancercenter.com.

About TomoTherapy Incorporated

TomoTherapy Incorporated has developed, manufactures and sells the TomoTherapy Hi·Art treatment system, an advanced radiation therapy system for the treatment of a wide variety of cancers. 

Source: TomoTherapy Incorporated